HSBC Holdings’s Immuneering IMRX Stock Holding History

HSBC Holdings’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37,771	Closed	-$198K	–	3067
2026 Q1	$198K	Buy	+37,771	New	+$194K	﹤0.01%	2619

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

HSBC Holdings's IMRX Position: Q2 2026 in Review

HSBC Holdings sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 37,771 shares — an estimated $198K sold.

HSBC Holdings first reported a position in IMRX in Q1 2026 and held it in 1 quarter. The position peaked at $198K in Q1 2026. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

HSBC Holdings reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
HSBC Holdings sold 37,771 Immuneering shares in Q2 2026, an estimated $198K.
HSBC Holdings first reported a position in Immuneering in Q1 2026 and held it in 1 quarter.
HSBC Holdings's Immuneering position peaked at $198K in Q1 2026.
112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.